H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate salt
Modify Date: 2024-01-11 02:06:36
H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate salt structure
|
Common Name | H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate salt | ||
|---|---|---|---|---|
| CAS Number | 283609-79-0 | Molecular Weight | 458.595 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 817.8±65.0 °C at 760 mmHg | |
| Molecular Formula | C21H42N6O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 448.4±34.3 °C | |
Use of H-Leu-Ser-Lys-Leu-NH2 trifluoroacetate saltLSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis. |
| Name | LSKL-NH2 |
|---|---|
| Synonym | More Synonyms |
| Description | LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis. |
|---|---|
| Related Catalog | |
| In Vitro | LSKL peptide is able to reduce liver fibrosis by inhibiting TGF-β activation[2]. |
| In Vivo | LSKL (1 mg/kg, i.p.) can easily traverse the blood brain barrier. LSKL peptide also alleviates hydrocephalus and improves long-term cognitive function following SAH. Moreover, LSKL peptide inhibits subarachnoid fibrosis after SAH. LSKL treatment significantly decreases the activation of TGF-β1 in the CSF in comparison with that in the SAH+PBS group[1]. LSKL peptide (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL peptide successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL peptide accelerates hepatocyte proliferation after hepatectomy[3]. |
| Animal Admin | Wild-type 8–12-week-old male mice (C57BL/6) are used for all experiments. LSKL TSP-1 inhibitory peptide is diluted to 5 mg/mL with normal saline. In the LSKL peptide group, LSKL peptide (30 mg/kg bodyweight in 6 mL/kg) is administered intraperitoneally before abdominal wall closure and at 6 h after the 70 per cent hepatectomy. In the normal saline group, saline (6 mL/kg) is given intraperitoneally at the same time points. In the sham-operated group, laparotomy is performed and the incision is sutured after normal saline (6 mL/kg) have been administered intraperitoneally. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 817.8±65.0 °C at 760 mmHg |
| Molecular Formula | C21H42N6O5 |
| Molecular Weight | 458.595 |
| Flash Point | 448.4±34.3 °C |
| Exact Mass | 458.321655 |
| LogP | -0.49 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.521 |
| Storage condition | -20°C |
| L-Leucinamide, L-leucyl-L-seryl-L-lysyl- |
| L-Leucyl-L-seryl-L-lysyl-L-leucinamide |
| H-Leu-Ser-Lys-Leu-NH2 |
| LSKL, Inhibitor of Thrombospondin (TSP-1) |